Levothyroxine Therapy Doesn’t Raise CVD Risk in Women With Hypothyroidism

Fresh research offers reassurance to women taking levothyroxine for hypothyroidism: the medication doesn’t appear to increase their long-term risk of cardiovascular disease (CVD) compared to women without thyroid conditions. Published in Thyroid on March 10, 2026, the study analyzed data from nearly 2,700 women over a period of decades, finding no significant difference in CVD events between those treated with levothyroxine and those without a thyroid diagnosis. This finding addresses growing concerns about a potential link between thyroid hormone levels and heart health in patients on levothyroxine.

Understanding the Study and Its Findings

The analysis, led by Matthew Ettleson, MD, of the University of Chicago, drew on data from the Study of Women’s Health Across the Nation (SWAN), a long-term observational study following women through midlife. Dr. Ettleson explained that the research aimed to clarify whether the common practice of levothyroxine treatment, which can sometimes lead to abnormal thyroid-stimulating hormone (TSH) levels, might inadvertently elevate CVD risk.

Researchers followed participants for up to 25 years, tracking diagnoses of myocardial infarction, stroke, heart failure, and other CVD events. The study included 2,647 women, with approximately 15.9% reporting hypothyroidism and receiving levothyroxine treatment at some point during the study period. The remaining 84.1% had no history of thyroid disease. CVD events occurred in 8.5% of the total study group, with a rate of 7.8% among those taking levothyroxine, and 8.6% among those without thyroid disease – a difference that was not statistically significant.

“We wanted to better understand the potential risk for CVD in women treated with levothyroxine for hypothyroidism given that of evidence that has emerged within the last 10 years or so that abnormal thyroid hormone levels are associated with CVD events in levothyroxine-treated patients,” Ettleson told Healio. “We also know that abnormal [thyroid-stimulating hormone] levels are common in people treated with levothyroxine. We could infer that, as a group, women treated with levothyroxine were being exposed to excess CVD risk. We wanted to test this hypothesis.”

What Does This Mean for Patients?

The findings are largely reassuring for women with hypothyroidism who rely on levothyroxine to manage their condition. Levothyroxine is a synthetic thyroid hormone used to replace what the thyroid gland isn’t producing, and it’s a cornerstone of hypothyroidism treatment. The study suggests that, when appropriately managed, the medication doesn’t inherently increase the risk of heart problems. However, it’s crucial to understand the nuances of the research.

The study focused specifically on women. While the findings are encouraging, it’s not yet clear whether the same holds true for men or for different age groups. Ettleson noted that future research should investigate CVD risk in older adults taking levothyroxine, as well as explore the impact of varying TSH targets during treatment. TSH levels are used to monitor the effectiveness of levothyroxine dosage, and optimal levels can vary between individuals.

It’s also important to remember that this was an observational study, meaning it can show associations but cannot prove cause and effect. Other factors, such as lifestyle choices and pre-existing health conditions, play a significant role in CVD risk. The study did identify several factors associated with increased CVD risk, including financial hardship, smoking, high diastolic blood pressure, and elevated fasting glucose levels. Conversely, postmenopausal status and higher HDL cholesterol levels were associated with lower risk.

Beyond Levothyroxine: A Broader View of CVD Risk

Cardiovascular disease remains a leading cause of death for women globally, according to the World Health Organization. While this study alleviates concerns about levothyroxine itself, it underscores the importance of addressing modifiable risk factors for CVD, such as diet, exercise, and smoking cessation.

The SWAN study also highlighted the importance of managing other health conditions that contribute to CVD risk. Women with financial difficulties, for example, faced a 52% higher risk of CVD events, suggesting that socioeconomic factors can significantly impact cardiovascular health.

The Role of TSH Levels and Treatment Optimization

The study’s sensitivity analyses, which examined subgroups based on TSH levels, found no difference in CVD risk between levothyroxine-treated groups and those without thyroid disease. This suggests that even in cases of suboptimal levothyroxine treatment – where TSH levels may not be perfectly within the target range – the medication didn’t appear to significantly increase CVD risk in this study population.

However, Ettleson cautioned that this doesn’t mean suboptimal treatment is acceptable. “A conclusion that could be drawn here is that if there was suboptimal treatment of levothyroxine in the SWAN group, it was not sufficient to cause the ‘average woman on levothyroxine’ to have a higher chance of a CVD event,” he said. “The study certainly supports the heart safety of optimal treatment of levothyroxine in women postmenopause. However, on an individual basis for women experiencing suboptimal treatment, we cannot say from these data.”

What’s Next in Thyroid and Cardiovascular Research?

Researchers are continuing to investigate the complex relationship between thyroid hormone levels and cardiovascular health. Future studies will likely focus on refining levothyroxine dosing strategies to optimize TSH levels and minimize potential risks. There’s also growing interest in personalized medicine approaches, which take into account individual factors such as genetics and lifestyle to tailor treatment plans.

Ongoing surveillance and data analysis, like that conducted through the SWAN study, are crucial for identifying emerging trends and informing clinical guidelines. Patients with hypothyroidism should continue to work closely with their healthcare providers to ensure their thyroid hormone levels are appropriately managed and to address any other risk factors for cardiovascular disease.